We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Four-in-One Test Kit for Detecting Influenza A, Influenza B, RSV and SARS-CoV-2 Set to Launch in November

By LabMedica International staff writers
Posted on 24 Sep 2020
Print article
Illustration
Illustration
A new four-in-one test kit for detecting influenza A, influenza B, RSV and SARS-CoV-2 is set to be launched in the coming month of November before the flu season begins in the Northern hemisphere.

Abacus Diagnostica (Turku, Finland) is developing the four-in-one test kit and plans to seek CE IVD approval for the multiplexed assay detecting influenzas, RSV and SARS-CoV-2. Since the beginning of COVID-19 outbreak, the company has been developing SARS-CoV-2 diagnostics. In July 2020, its SARS-CoV-2 assay for the GenomEra CDX system received the CE IVD approval for the European market.

GenomEra SARS-CoV-2 is a rapid multiplex RT-PCR test for the detection of RdRp and E genes. RNA extraction is not needed, which dramatically reduces the time and workload of the laboratory personnel. Results are automatically and reliably reported by GenomEra software.The sample preparation is simple and requiring only one quick heating step. GenomEra Test Chips contain all the reagents needed for RT-PCR, which enables performing the testing in laboratories without any earlier experience of PCR. The results from the PCR-based COVID-19 test are available within 75 minutes. Because of the ease and rapidity of the system, many hospitals are using the assay for urgent samples such as testing hospital personnel.

In addition to the COVID-19 assay, the company has been working on a four-in-one test kit for detecting influenza A, influenza B, RSV and SARS-CoV-2. In the Northern hemisphere, the flu season is approaching now on top of the COVID-19 pandemic. The company plans to seek the CE IVD approval for the multiplexed assay detecting influenzas, RSV and SARS-CoV-2. The time frame is set by the approaching flu season. Abacus is aiming for the market launch with well available, CE IVD approved four-in-one assay in November, in a good time before the flu season begins.

“The COVID-19 testing is essential to manage and control the pandemic. When everyone is focused on COVID-19, there is a risk of delays on the diagnosis and treatment of other infections,” said Mr. Erno Sundberg, the CEO of Abacus Diagnostica. “It would benefit the patients and save the resources of the health care system to test more than one pathogen at a time. The flu season awaits in the shade of COVID-19 outbreak, and our new assay will help to bring it on sight as soon as it sets off.”

Related Links:
Abacus Diagnostica

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
COVID-19 Rapid Test
AQ+ COVID-19 Ag Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.